Location of Repository

Bortezomib a safety treatment for patients with Multiple Myeloma and Cystic Fibrosis

By Fabiana Gentilini, Anna Levi, Vincenzo Federico, Eleonora Russo, Robin Foà and Maria Teresa Petrucci

Abstract

Introduction: Bortezomib is a proteasome inhibitor that targets myeloma cell and its bone marrow micro-environment. Intravenous Bortezomib (1.3 mg/m2 administered on days 1,4,8 and 11 of a 21 day cycle), with or without dexamethasone, is effective and well tolerated in patients with relapsed/refractory multiple myeloma (MM). Methods:  We treated a MM patient with Cystic Fibrosis with Bortezomib alone to avoid the use of corticosteroid and consequently the risk of lung infection reactivations, first of all due to the patient Pseudomonas aeruginosa colonization. Bortezomib was administrated at 1.3 mg/m2 on days 1,4,8 and 11 with a 10 day rest period  and four 21-day cycles were administered. We evaluate the treatment response and toxicity. Results: After four cycles of therapy the patient achieved a  very good partial response (VGPR) according to the IMWG response criteria, without clinically significant side effects. Conclusions: Bortezomib can be successfully utilized for the management of this difficult disease situatio

Topics: Multiple Myeloma, Cystic Fibrosis, Bortezomib, Diseases of the blood and blood-forming organs, RC633-647.5
Publisher: PAGEPress Publications
Year: 2012
DOI identifier: 10.4084/mjhid.2012.035
OAI identifier: oai:doaj.org/article:942f1d881d474cd8801b8f4085d31465
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/2035-3006 (external link)
  • http://www.mjhid.org/index.php... (external link)
  • https://doaj.org/article/942f1... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.